{"id":29286,"date":"2026-07-01T19:07:00","date_gmt":"2026-07-01T17:07:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=20358f081f3dfab2ace66d7929dfabe0"},"modified":"2026-07-01T19:07:00","modified_gmt":"2026-07-01T17:07:00","slug":"spry-investor-alert-levi-korsinsky-investigates-ars-pharmaceuticals-spry-for-potential-securities-fraud","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=29286","title":{"rendered":"SPRY Investor Alert: Levi & Korsinsky Investigates ARS Pharmaceuticals (SPRY) for Potential Securities Fraud"},"content":{"rendered":"

\nARS Pharmaceuticals guided investors toward broad commercial coverage of Neffy, including the achievement of approximately 80% coverage -- the July 2026 payer cycle delivered zero new formulary additions, and SPRY dropped more than 23%.<\/i><\/p><\/a><\/a>

NEW YORK--(BUSINESS WIRE)--Shareholders who held ARS Pharmaceuticals (NASDAQ: SPRY) stock watched the value drop more than 23% in after-hours trading on June 24, 2026, after the Company disclosed that Neffy\u00ae received no new commercial formulary additions or payer-coverage decisions in the July 1, 2026 review cycle. Investors who lost money on SPRY are encouraged to submit their information to discuss their legal rights<\/a>. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com<\/a> or by telephone at (212) 363-7500.<\/p>

\nDuring the Q4 2024 earnings call on March 20, 2025, Chief Commercial Officer Eric Karas commented that \u201cthe goal is for Neffy to achieve more than 60% commercial coverage by the end of the first quarter.\" CEO Richard Lowenthal added that ARS anticipated \"being on formulary for CVS Caremark, Anthem, Aetna and others by July 1 in time for the summer peak prescribing season.\" The July 1, 2026 payer-review cycle produced zero new formulary additions for Neffy\u00ae.<\/p>

\nOn November 10, 2025, during the Q3 2025 earnings call, Lowenthal characterized Neffy\u2019s prescription growth slowdown as \"a one time event\" and to return to quarter-over-quarter growth.\u201d The Company's April 29, 2026 proxy filing claimed \"over 90% overall commercial coverage\" with no reference to pending payer-cycle risk or the possibility that no new formulary wins would materialize.<\/p>

\nSPRY shareholders who suffered losses may click here to discuss their legal rights with Levi & Korsinsky<\/a>. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com<\/a> or by telephone at (212) 363-7500.<\/p>

\nLevi & Korsinsky, LLP<\/b> -- Top 50 securities litigation firm (ISS, seven consecutive years). Over 70 professionals. Hundreds of millions recovered.<\/p>

\nFrequently Asked Questions About the SPRY Investigation<\/p>

\nQ: Which statements are being investigated as potentially misleading?<\/b> A: The investigation concerns whether ARS Pharmaceuticals made materially false or misleading statements regarding Neffy\u00ae commercial coverage outlook, including projections of near-term achievement of broad (~80%) payer coverage and expectations that CVS Caremark would add Neffy to its formulary by the July 1, 2026 cycle.<\/p>

\nQ: Who is eligible to participate in the SPRY investigation?<\/b> A: Investors who purchased SPRY stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.<\/p>

\nQ: What do SPRY investors need to do right now?<\/b> A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at jlevi@levikorsinsky.com<\/a> or (212) 363-7500. No immediate action is required to remain eligible to participate in the investigation.<\/p>

\nQ: What happens after I contact Levi & Korsinsky?<\/b> A: An attorney will review your trading history at no cost and provide an initial assessment of your potential recovery.<\/p>

\nQ: What if I already sold my SPRY shares -- can I still recover losses?<\/b> A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought SPRY and sold at a loss may still participate in the investigation.<\/p>

\nQ: Do I need to go to court or give testimony?<\/b> A: No. Participating in the investigation does not require court appearances or depositions. If legal action is later pursued, the overwhelming majority of affected investors never appear in court either.<\/p>

\nQ: What does it cost me to participate?<\/b> A: Nothing. Securities investigations and any resulting actions are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs.<\/p>

\nQ: What if I live outside the United States?<\/b> A: U.S. securities fraud investigations generally cover purchases on U.S. exchanges regardless of the investor's country of residence.<\/p> Contacts<\/b>

\nLevi & Korsinsky, LLP\nJoseph E. Levi, Esq.\nEd Korsinsky, Esq.\n33 Whitehall Street, 27th Floor\nNew York, NY 10004\njlevi@levikorsinsky.com<\/a>Tel: (212) 363-7500\nFax: (212) 363-7171<\/p>","protected":false},"excerpt":{"rendered":"

ARS Pharmaceuticals guided investors toward broad commercial coverage of Neffy, including the achievement of approximately 80% coverage — the July 2026 payer cycle delivered zero new formulary additions, and SPRY dropped more than 23%.NEW YORK–(BUSI…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-29286","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/29286","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=29286"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/29286\/revisions"}],"predecessor-version":[{"id":29287,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/29286\/revisions\/29287"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=29286"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=29286"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=29286"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}